Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other financing activities (2016 - 2024)

Tg Therapeutics (TGTX) has 4 years of Other financing activities data on record, last reported at $31000.0 in Q4 2024.

  • For Q4 2024, Other financing activities changed N/A year-over-year to $31000.0; the TTM value through Dec 2025 reached $889000.0, changed 0.0%, while the annual FY2024 figure was $889000.0, 611.2% up from the prior year.
  • Other financing activities reached $31000.0 in Q4 2024 per TGTX's latest filing, down from $858000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $858000.0 in Q3 2024 and bottomed at $31000.0 in Q4 2024.